STOCK MARKET BSE NSE

Lupin, TB Alliance join hands for new therapy for drug-resistant Tuberculosis

The Mumbai-based company said it intends to commercialise the medicine in around 140 countries and territories, including many of the highest TB burden nations around the world.

Published: 06th September 2021 01:20 PM  |   Last Updated: 06th September 2021 01:20 PM   |  A+A-

tuberculosis

For representational purposes

By PTI

NEW DELHI: Drugmaker Lupin on Monday said non-profit drug developer TB Alliance has granted it a non-exclusive licence to manufacture anti-TB drug pretomanid as part of the three-drug BPaL regimen.

The Mumbai-based company said it intends to commercialise the medicine in around 140 countries and territories, including many of the highest TB burden nations around the world.

"As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health," Lupin Managing Director Nilesh Gupta said in a statement.

TB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering high-quality TB therapies -- will help further enable widespread access to the novel regimen while promoting a competitive market to drive affordability.

Tuberculosis is one of humanity's oldest, deadliest, and most persistent diseases.

The BPaL regimen offers the TB community the first all-oral, six-month treatment for highly resistant forms of drug resistant-TB.

Lupin is the largest supplier of first-line anti-TB drugs in the world, the drugmaker stated.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp